Documents

Use of a new plant extract-based product in the early postoperative care of patients with productive rhinosinusitis

POPOVICH, V.
Professor, Doctor of Medicine,
State Academy of Medicine,
Ivano-Frankovsk, Ukraine.

SAVCHUK, O.
Doctor of Medicine,
State Academy of Medicine,
Ivano-Frankovsk, Ukraine.
Otorhinolaryngology, Kiev

Therapeutics and Clinical Risk Management.
Special Issue in Spanish. Supplement I 2006.
Therapeutics and clinical risk management 2006 - PDF


ABSTRACT

The incidence of chronic conditions affecting the paranasal sinuses continues to increase, in spite of the therapies currently available. Endoscopic surgery seeks to restore drainage and clearance of the paranasal sinuses.
However, in spite of the progress that has been made in this technique, there is still a significant percentage of patients who experience a recurrence of the obstruction after surgery. Among other reasons, this is due to the inflammatory congestive process, tissue oedema and hyperaemia after the aggression produced by the surgery. It becomes particularly important to use products that facilitate natural nasal and paranasal secretion and help remove the accumulated content.

The goal pursued by this study was to determine the usefulness of a new plant extract-based product in surgical patients with productive rhinosinusitis and cysts of the maxillary sinuses after administration in the early postoperative period.
Our results show that its use as monotherapy after surgery gives rise to a rapid clearance of the nasal meatus and sinuses, with normal rhinoscopic findings being obtained between the fifth and sixth day after administration of the preparation.


Use in the early postoperative care of patients with productive rhinosinusitis - Full article

Therapeutics and clinical risk management 2006 - Index

Hartington Pharma owns Nasodren® for sinusitis treatment